An interferon-free
regimen of sofosbuvir plus ledipasvir (Harvoni)
taken with ribavirin for 12 or 24 weeks led to sustained virological response
in nearly all HCV genotype 1patients
with fibrosis or less-advanced liver cirrhosis, researchers reported at the American
Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in
Boston, United States. Response rates